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Abstract: Multiple systems tauopathy with presenile dementia (MSTD), a form of frontotemporal dementia with 
parkinsonism-17 with tau inclusions (FTDP-17T), is a neurodegenerative disorder caused by an (a) to (g) transition 
at position +3 of intron 10 of the microtubule associated protein tau (MAPT) gene. The mutation causes overex-
pression of 4 repeat (4R) tau isoforms with increased 4R/3R ratio leading to neurodegeneration. Clinically, these 
patients primarily present with behavioral variant FTD (bvFTD) and show disinhibition, disordered social comport-
ment, and impaired executive function, memory, and speech. While altered glucose metabolism has been reported 
in subjects with sporadic bvFTD, it has yet to be investigated in an FTDP-17 sample of this size. In this study, eleven 
mutation carriers (5 males; mean age = 48.0 ± 6.9 years) and eight non-carriers (2 males; mean age = 43.7 ± 12.0 
years) from a MSTD family were imaged using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET). 
Eight of the MAPT intron 10 +3 mutation carriers met diagnostic criteria for bvFTD at the time of the PET scan, while 
three MAPT intron 10 +3 carriers were not cognitively impaired at the time of scan. Non-carriers had no clinically-
relevant cognitive impairment at the time of the PET scan. Additionally, ten mutation carriers (5 males; mean age = 
48.04 ± 2.1 years) and seven non-carriers (2 males; mean age 46.1 ± 4.1 years) underwent magnetic resonance 
imaging (MRI) which is an expanded sample size from a previous study. Seven MAPT mutation carriers met diag-
nostic criteria for bvFTD at the time of the MRI scan. Images were assessed on a voxel-wise basis for the effect 
of mutation carrier status. SPM8 was used for preprocessing and statistical analyses. Compared to non-carriers, 
MAPT mutation carriers showed lower [18F]FDG uptake bilaterally in the medial temporal lobe, and the parietal and 
frontal cortices. Anatomical changes were predominantly seen bilaterally in the medial temporal lobe areas which 
substantially overlapped with the hypometabolism findings. These anatomical and metabolic changes overlap previ-
ously described patterns of neurodegeneration in MSTD patients and are consistent with the characteristics of their 
cognitive dysfunction. These results suggest that neuroimaging can describe the neuropathology associated with 
this MAPT mutation.
Keywords: Multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia with parkin-
sonism-17 with tau inclusions (FTDP-17T), behavioral variant frontotemporal dementia, [18F]fluorodeoxyglucose 
positron emission tomography ([18F]FDG PET), microtubule associated protein tau (MAPT), magentic resonance 
imaging (MRI), neuroimaging
Introduction 
Frontotemporal dementia (FTD) is a clinically, 
genetically, and pathologically heterogeneous 
neurodegenerative disorder which is consid-
ered to be the second leading cause of early 
onset dementia after Alzheimer’s disease [1]. 
FTD is characterized by marked changes in 
behavior, personality, executive function, and 
language. 
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Approximately 40-50% of patients with FTD 
report a positive family history of dementia, 
with 10% of these cases having an autosomal 
dominant inheritance pattern [2]. Up to 30% of 
familial FTD cases have been linked to genetic 
variations in the microtubule associated pro-
tein tau (MAPT) gene located at 17q21 [3]. 
These patients typically present with FTD with 
parkinsonism and with tau inclusions (FTDP-
17T). Additional mutations in progranulin 
(PGRN), which is also located at 17q21, have 
been linked to familial FTD. However, histopath-
ologically, mutations in PGRN are not associat-
ed with tau inclusions, while MAPT mutations 
are associated with tau pathology [4-6]. 
A family with multiple systems tauopathy with 
presenile dementia (MSTD), a form of FTDP-
17T, was discovered by our group to have an (a) 
to (g) transition in MAPT intron 10 +3 [7-10]. In 
the normal adult human brain, six tau isoforms 
are expressed from the alternative splicing of 
MAPT exons 2, 3, and 10. The exclusion or 
inclusion of exon 10 leads to the expression of 
three (3R) or four (4R) repeat microtubule-bind-
ing domains, respectively, at a balanced ratio 
[11, 12]. The (a) to (g) transition in this family 
leads to an overproduction of the 4R tau iso-
form. Clinically, these patients have heteroge-
neous presentations, but present frequently as 
behavioral variant FTD with changes in person-
ality, such as disinhibition and disordered social 
conduct, and impaired executive function, 
memory, and speech [13, 14]. Both clinical 
imaging and post-mortem assessment show 
marked neurodegeneration in medial temporal 
and frontal regions [15].
Previous studies have investigated grey matter 
(GM) loss and hypometabolism in sporadic 
bvFTD. Reduced glucose uptake measured 
using [18F]fluorodeoxyglucose ([18F]FDG) posi-
tron emission tomography (PET) has previously 
been identified in the frontal and temporal 
lobes, anterior cingulate cortex, anterior insula, 
and subcortical regions [16-23]. Additionally, 
[18F]FDG PET studies with other FTDP-17 fami-
lies showed a reduction in glucose metabolism 
in temporal cortices, parietal cortices, hippo-
campi, and the amygdalae, although these 
samples were quite small [24-26]. Studies have 
also shown GM loss in the frontotemporal lobe 
regions, insula, and putamen [16, 25, 27, 28]. 
However, anatomical changes and glucose 
metabolism in the brain has yet to be reported 
in this MSTD family or in a FTDP-17 sample of 
this size. 
The goal of the present study is to investigate 
changes in glucose metabolism with [18F]FDG 
PET in MSTD to better define the metabolic fea-
tures associated with MAPT mutations and fur-
ther characterize this large MSTD family. 
Magnetic resonance was also utilized for com-
parison with [18F]FDG PET using an expanded 
sample from Spina et al [15]. While the informa-
tion derived from these two imaging modalities 
may identify similar abnormalities in the same 
structure, there may be a temporal ordering of 
the onset of abnormalities detected by these 
complementary techniques. For example, glu-
cose hypometabolism may precede GM atro-
phy as is observed in other familial neurode-
generative disorders [29]. We hypothesized 
that the MAPT intron 10 +3 mutation causes 
Table 1. Demographic and neuropsychological data 
Symptomatic  
carrier (n = 8) Asymptomatic carrier (n = 3) Non-carrier (n = 8) p-value
Age (years) 50.1 ± 5.4 42.55 ± 8.7 43.7 ± 12.0 0.313
Gender (M, F) 5, 3 0, 3 2, 6 0.106
Education (years) 12.75 ± 0.9 14.3 ± 2.1 13.4 ± 1.3 0.764
% APOE ε4+ 25 0 62.5 0.106
MMSE Total Score 23.6 ± 5.6 28.3 ± 0.6 27 ± 1.6 0.189
COWA Total Score* 22.1 ± 10.6 33.7 ± 6.7 38.86 ± 10 0.045***
Block Design Total* 23.4 ± 12.8 33.3 ± 10 34.43 ± 4.2 0.235
Word List Imm Total** 11.75 ± 5.5 28 ± 1.4* 21.9 ± 4.6 0.006***
Word List Del Total** 2.75 ± 2 9.5 ± 0.7* 8.13 ± 1.6 < 0.001***
M = male; F = female; MMSE = Mini-Mental State Exam; COWA = Controlled Oral Word Association; Word List Imm = CERAD 
Word List – Immediate Recall; Word List Del = CERAD Word List – Delayed Recall. Mean ± Standard Deviation. *Missing one 
non-carrier. **Missing one asymptomatic carrier. ***Significant at p < 0.05. 
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reduced glucose metabolism in carriers within 
this MSTD family, particularly in the medial tem-
poral and frontal areas that are known to be 
susceptible to atrophy in bvFTD. We also 
hypothesized that clinically-affected mutation 
carriers would show greater glucose hypome-
tabolism in target areas than carriers who are 
not yet cognitively impaired. 
Methods
Subjects
Nineteen participants, including eleven MAPT 
intron 10 +3 mutation carriers ((eight symptom-
atic (SC), three asymptomatic (AC)) and eight 
non-carriers (NC; Table 1), underwent neuro-
logical and cognitive assessments, as well as 
[18F]FDG PET and structural magnetic reso-
nance imaging (MRI) at the Indiana Alzheimer 
Disease Center. Demographic information for 
four of these SCs has previously been reported 
[15]. Participants were diagnosed with bvFTD 
using standard criteria [13, 30] from neuropsy-
chological testing, neurological examination, 
informant interviews, and past medical records. 
Genotyping
Genotyping of the MAPT intron 10 +3 mutation 
was performed as previously described [15]. 
Briefly, genomic DNA was extracted using stan-
dard protocols [15] and the purified DNA prod-
uct from PCR amplification was compared to 
the known MAPT exon 10 sequence previously 
determined [7]. 
Magnetic resonance imaging acquisition and 
processing
All participants underwent a structural MRI 
scan within 1.00 ± 1.11 days (range: 1-5 days) 
of the [18F]FDG PET scan. Seventeen partici-
pants, including ten MAPT intron 10 +3 muta-
tion carriers (7 SCs, 3 ACs) and seven NCs, 
underwent a single T1-weighted SPGR volumet-
ric scan on a 1.5T GE Signa scanner as previ-
ously described [15]. Two participants, one 
affected mutation carrier and one non-carrier, 
received a single T1-weighted MPRAGE volu-
metric scan on a 3T Siemens Trio scanner. 
Structural MRI scans were processed using 
voxel based morphometry (VBM) in SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/) using previ-
ously described techniques [31]. Briefly, scans 
were co-registered to a T1-weighted template 
and segmented into GM, white matter, and 
cerebrospinal fluid compartments using stan-
dard templates with bias correction. 
Unmodulated GM images were normalized to 
Montreal Neurologic Institute (MNI) space as 1 
x 1 x 1 mm voxels and smoothed with an 8mm 
full-width half maximum (FWHM) Gaussian ker-
nel. All scans underwent extensive quality con-
trol at all processing steps. Only smoothed, nor-
malized GM images generated from the SPGR 
volumes acquired on the 1.5T GE scanner were 
used in the VBM analysis, given the differences 
in data acquisition for 3T scans. Parameters 
generated from the structural MRI segmenta-
tion were also used for [18F]FDG PET process-
ing as described below (see PET Data 
Acquisition and Imaging Processing).
PET data acquisition and image processing
All participants also underwent a [18F]FDG PET 
scan, acquired on a Siemens EXACT HR+ scan-
ner. After positioning within the scanner, a 
10-minute transmission scan using three inter-
nal rod sources was acquired for attenuation 
correction. A 60-min dynamic acquisition proto-
col was then initiated with the injection of 
approximately 10 mCi of [18F]FDG using the fol-
lowing frame sequence: 12 x 5 s, 4 x 15 s, 2 x 
30 s, 7 x 60 s, 10 x 300 s. [18F]FDG scans were 
reconstructed using the manufacturer’s soft-
ware (CTI Molecular Imaging Inc.; Knoxville, TN) 
with the filtered back-projection algorithm. 
Corrections for scatter, randoms, and attenua-
tion were applied.
Reconstructed [18F]FDG scans were processed 
using standard techniques. Using SPM8, scans 
were converted from ECAT to NiFTI format, 
coregistered to the structural MRI scan from 
the same visit, motion corrected, and normal-
ized to MNI space using matrices from the 
same time-point MRI segmentation. A static 
[18F]FDG image from 30-60 minutes was creat-
ed from the appropriate frames, intensity nor-
malized using a cerebellar GM reference region 
to create a standardized uptake value ratio 
(SUVR) image for each participant, and 
smoothed with an 8 mm FWHM kernel. The 
SUVR images were then used for further analy-
sis as described below. 
Image analysis
Within the SPM8 framework, an analysis of 
covariance (ANCOVA) was performed on nor-
malized MRI GM density and [18F]FDG PET 
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SUVR maps to compare the effect of mutation 
status (carrier vs. non-carrier) on GM density 
and [18F]FDG uptake on a voxel-by-voxel basis. 
Age at scan and gender were used as covari-
ates for the [18F]FDG PET analysis. Age, gender, 
and total intracranial volume (ICV) were used 
as covariates for the GM density contrasts. In 
addition, since five of the NCs and two of the 
SCs were positive for apolipoprotein (APOE) ε4 
allele, which has been shown to affect glucose 
metabolism in late mid-life [32], we computed 
similar analyses for both [18F]FDG and GM den-
sity that also included APOE ε4 carrier status 
as a covariate. However, the inclusion of APOE 
ε4 carrier status did not significantly affect the 
observed results and thus was not included in 
the final reported results (data not shown). An 
explicit GM mask was applied to both MRI and 
PET analyses to restrict the search area. 
Significant findings were displayed using a 
threshold of p < 0.001 (uncorrected) for MRI, 
and a threshold of p < 0.01 (uncorrected) for 
[18F]FDG PET; for both analyses, minimum clus-
ter size was (k) = 50 voxels. A composite image 
using the significant clusters for MRI and [18F]
FDG PET was created to determine areas of 
MRI and PET overlap between mutation carri-
ers and NCs. MarsBaR toolbox (version 0.42) in 
SPM was used to extract mean GM density and 
mean glucose uptake for the significant medial 
temporal lobe (MTL) clusters from MRI and PET 
analyses, respectively. Note that MRI results 
for four MAPT 10 +3 mutation carriers has 
been previously reported [15].
Statistical analysis
While the three diagnostic groups were too 
small to do voxel-based imaging analysis, we 
had a special interest in the AC group and want-
ed to determine if they showed any regional 
metabolic, GM density, and/or neuropsycho-
logical differences from NC and SC partici-
pants. An ANCOVA was used to test for the 
association of continuous demographic vari-
ables and neuropsychological test performance 
with mutation and diagnostic status. Gender 
was assessed with mutation and diagnostic 
status using a chi-square test. Age and years of 
education were used as covariates when evalu-
ating neuropsychological test scores. Z-scores 
of left and right mean MTL GM density and MTL 
glucose uptake from the significant MTL clus-
ters identified in previous voxel-wise analyses 
were calculated for each participant using 
means and standard deviations from the NC 
group. The left and right z-scores were then 
averaged to create a bilateral mean GM density 
and bilateral mean glucose uptake z-score for 
each participant. ANCOVA was again used to 
test the association of diagnostic/mutation 
groups (SC, AC, NC) with MTL GM density and 
glucose uptake z-scores. Age and gender were 
used as covariates for the assessment of MTL 
glucose uptake, while age, gender, and ICV 
were used as covariates for the evaluation of 
MTL GM density. Pairwise contrasts between 
groups were adjusted for multiple comparisons 
using a Bonferroni correction. Linear regres-
sion was used to compare MTL GM density and 
MTL glucose uptake. All statistical analyses 
were done in SPSS (version 20.0, Chicago, IL) 




Demographics and neuropsychological test 
results are displayed in Table 1. Although not 
statistically significant, SCs were on average 
older and more likely to be male than the other 
groups. Thus, age and gender were used as 
covariates in all subsequent neuroimaging 
analyses. As expected, a significant association 
between diagnostic/mutation status group and 
neuropsychological performance was observed 
on the COWA (p = 0.045) and the CERAD Word 
List Immediate Recall (p = 0.006) and Delayed 
Recall (p < 0.001). Upon post-hoc analysis, SCs 
showed poorer performance on the COWA than 
NCs (p = 0.044). In addition, ACs and NCs 
showed better performance than SCs on the 
CERAD Word List Immediate Recall (SC vs. AC, 
p = 0.022; SC vs. NC, p = 0.012) and Delayed 
Recall (SC vs. AC, p = 0.004; SC vs. NC, p < 
0.001).
MRI
Cerebral atrophy was observed in MAPT muta-
tion carriers relative to NCs. Specifically, 
decreased GM density was observed bilaterally 
in the MTL, including in the parahippocampal 
gyri, hippocampi, entorhinal cortices, uncus, 
and amygdala, as well as in the caudate nucle-
us (Figure 1; voxel-wise threshold of p < 0.001 
(uncorrected for multiple comparisons); k = 50 
voxels). GM atrophy was also observed in muta-
tion carriers in the precuneus, insula, medial 
and superior frontal gyri, and the precentral 
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gyrus, in addition to other regions of the frontal, 
parietal, occipital, and lateral temporal lobes 
(Figure 1). However, unlike in previous bvFTD 
studies, there were surprisingly few differences 
between mutation carriers and NCs in the pre-
frontal cortex and cingulate gyrus. 
Figure 1. Voxel-wise analysis of the effect of MAPT intron 10 +3 mutation status on GM density. Whole-brain GM 
density was compared between carriers of the MAPT intron 10 +3 mutation and non-carriers. Mutation carriers 
show GM atrophy relative to non-carriers in regions of the medial temporal lobe (A) and other cortical and subcorti-
cal regions (B). Differences between mutation carriers and non-carriers are displayed at a voxel-wise threshold of 
p < 0.001 (uncorrected for multiple comparisons) and minimum cluster size (k) = 50 voxels. Age, gender, and total 
intracranial volume were used as covariates. 
Figure 2. Voxel-wise analysis of the effect of MAPT intron 10 +3 mutation status on glucose metabolism. Whole-
brain glucose metabolism was compared between carriers of the MAPT intron 10 +3 mutation and non-carriers. 
Mutation carriers showed hypometabolism relative to non-carriers in the medial temporal lobe (A), caudate nucleus 
(B), anterior cingulate gyrus (C), and in frontal, parietal, and temporal cortices (D). Group differences are displayed 
at a voxel-wise threshold of p < 0.01 (uncorrected for multiple comparisons) and minimum cluster size (k) = 50 
voxels. Age and gender were used as covariates. 
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The most striking GM atrophy in mutation carri-
ers was seen bilaterally in the MTL (Figure 1), 
as has been previously shown [15]. Further 
analysis of these regions to evaluate distribu-
tion of atrophy among diagnostic/mutation 
groups showed a significant overall difference 
in GM density z-score (Figure 3, p < 0.001). 
Pairwise comparisons showed reduced GM 
density in both AC and SC relative to NC (NC vs. 
AC, p = 0.022; NC vs. SC, p < 0.001). GM atro-
phy in AC was intermediate between that of NC 
and SC, with significantly more atrophy than NC 
but less atrophy than SC (AC vs SC, p = 0.01).
[18F]FDG PET
Bilateral hypometabolism was observed in 
mutation carriers relative to NCs in regions of 
= 0.004) and NC and SC (p < 0.001) reached 
statistical significance, whereas the AC and SC 
groups (p = 0.154) were not significantly 
different. 
Comparison of MRI and [18F]FDG
In other familial neurodegenerative disorders 
(i.e. familial Alzheimer’s disease), hypometabo-
lism may precede brain atrophy [29]. Therefore, 
we investigated the relationship between MRI 
and PET findings in the MSTD sample. There 
was moderate overlap of the regions showing 
neurodegeneration and those showing glucose 
hypometabolism in mutation carriers relative to 
NCs, most especially in the MTL (Figure 4). 
While significant overlap can be seen in MTL 
structures such as the uncus, hippocampus, 
and parahippocampal gyrus, atrophy appeared 
Figure 3. Medial temporal lobe (MTL) GM density and glucose metabolism in 
carriers and non-carriers of the MAPT intron 10 +3 mutation. Mean GM den-
sity and glucose metabolism were extracted from the MTL clusters identified 
in the voxel-wise comparisons (Figures 1 and 2) using MarsBaR. Z-scores 
were then calculated and the effect of mutation and clinical status on GM 
atrophy and glucose hypometabolism was evaluated, covaried for age and 
gender. Total intracranial volume was also included in the analysis of GM 
atrophy. Significant differences between groups were observed for both GM 
density (p < 0.001) and glucose uptake (p < 0.001). Post-hoc comparisons 
of GM density showed a significant difference between all group pairs, with 
symptomatic carriers (SC) showing the greatest MTL atrophy and asymptom-
atic carriers (AC) showing intermediate MTL atrophy between SC and muta-
tion non-carriers (NC; NC vs. AC, p = 0.022; NC vs. SC, p < 0.001; AC vs SC, 
p = 0.01). Post-hoc comparisons of glucose uptake demonstrated significant 
greater glucose metabolism in NC relative to both carrier groups (NC vs. AC 
(p = 0.004) and NC vs. SC (p < 0.001)), but no difference between carriers 
based on clinical status (p = 0.154).
the MTL and limbic system, 
including the parahippocam-
pal gyri, hippocampi, entorhi-
nal cortices, amygdala, uncus, 
and the anterior cingulate cor-
tex, as well as in the caudate 
nucleus (Figure 2, Table 2). 
Some lateralization of hypo-
metabolism in mutation carri-
ers relative to non-carriers 
was observed with more 
reductions in glucose metabo-
lism in the right anterolateral 
temporal lobe than in the left. 
Other frontal and parietal cor-
tical regions also showed 
hypometabolism in mutation 
carriers relative to non-carri-
ers, including in the anterior 
prefrontal cortex, the medial 
and superior frontal gyri, and 
the postcentral gyrus (Figure 
2). 
Further examination of the dif-
ference in glucose metabo-
lism among the three groups 
in the MTL showed a signifi-
cant association of diagnos-
tic/mutation status with mean 
MTL glucose SUVR z-score 
(Figure 3; p < 0.001). The ACs 
again showed mean MTL glu-
cose uptake intermediate 
between the NC and SC. 
Comparisons of NC and AC (p 
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to be more widespread than hypometabolism 
in mutation carriers relative to NCs (Figures 3 
and 4). However, other regions, including the 
anterior cingulate cortex and caudate nucleus, 
showed very little or no overlap of GM atrophy 
and reduced glucose metabolism. When MTL 
atrophy and glucose metabolism measures 
were directly compared, reduced GM density 
was highly associated with reduced glucose 
hypometabolism (left: r = 0.93, p < 0.001; right: 
r = 0.88, p < 0.001; Figure 5). 
MTL is similar to findings from studies of other 
familial FTD with MAPT mutations [25, 27, 28, 
33-35]. However, contrary to other bvFTD stud-
ies, our results showed very little GM atrophy in 
the frontal lobes [36]. The MSTD patients did 
show anterior temporal atrophy, which is con-
sistent with the new diagnostic criteria for 
bvFTD [14]. The AC group showed a level of 
atrophy intermediate between the NC and SC 
groups, with significant differences detected 
between all groups. This suggests that neuro-
Table 2. Anatomical distribution of reduced glucose metabo-
lism for in MAPT intron 10 +3 carriers relative to non-carriers
MNI Coordinates
Location BA T-value x y z p-value
L. Inferior Frontal Gyrus 47 4.58 -26 10 -18 0.000
L. Inferior Parietal Lobule 40 3.11 -58 -32 46 0.004
L. Middle Frontal Gyrus 10 3.38 -26 66 12 0.002
6 2.92 -46 10 50 0.005
9 3.03 -52 26 34 0.004
L. Middle Temporal Gyrus 21 3.29 -56 2 -18 0.002
2.98 -64 -10 -12 0.005
2.68 -58 -18 -6 0.009
L. Superior Frontal Gyrus 10 2.83 -36 48 32 0.006
6 3.55 -20 6 70 0.001
3 -8 28 66 0.004
8 3.96 -6 44 52 0.001
3.13 -22 32 56 0.003
L. Superior Parietal Lobule 7 3.34 -28 -58 64 0.002
L. Superior Temporal Gyrus 10 4.77 -14 70 18 0.000
38 3.85 -22 14 -34 0.001
L. Thalamus 3.22 -8 -32 -4 0.003
L. Uncus 34 4.42 -18 2 -22 0.000
R. Anterior Cingulate 32 3.71 2 46 6 0.001
R. Caudate Body 3.98 16 22 16 0.001
3.57 14 12 20 0.001
R. Medial Frontal Gyrus 25 5.29 8 6 -22 0.000
R. Middle Frontal Gyrus 8 3.1 40 24 56 0.004
R. Middle Temporal Gyrus 21 3.92 64 -6 -12 0.001
R. Postcentral Gyrus 7 3.16 16 -52 72 0.003
R. Superior Frontal Gyrus 10 4.66 22 68 14 0.000
4.1 16 62 28 0.000
6 3.11 14 32 60 0.004
8 2.94 20 38 52 0.005
R. Superior Parietal Lobule 7 3.47 18 -68 58 0.002
R. Superior Temporal Gyrus* 38 5.99 44 16 -22 0.000
R. Uncus 34 4.57 20 4 -22 0.000
BA = Brodmann area; MNI = Montreal Neurologic Institute; L. = left; R. = right. 
p < 0.01, uncorrected. *Significant cluster for p < 0.05 at FWE-corrected.
Discussion
Although MRI and [18F]FDG PET 
studies have been reported for 
sporadic bvFTD [16-21, 24], few 
studies have investigated chang-
es in glucose metabolism or brain 
atrophy in FTDP-17T [24, 33]. Our 
findings show that individuals 
with the MAPT mutation at posi-
tion +3 of intron 10 have promi-
nent GM atrophy bilaterally in the 
MTL regions and reduced glucose 
metabolism in MTL regions and 
the prefrontal cortex, when com-
pared to NCs. Furthermore, ACs 
showed anatomical and metabol-
ic changes intermediate between 
the SC and NC participants.  We 
also observed substantial over-
lap in cortical atrophy and hypo-
metabolism, specifically in MTL 
regions. 
MRI findings
VBM results for four of the eleven 
MSTD patients used in this study 
have been previously reported, 
and showed extensive GM loss in 
the hippocampus, parahippocam- 
pal gyrus, insular cortex, and to a 
lesser extent, the anterior cingu-
late cortex, head of the caudate 
nucleus, posterolateral orbital 
cortex, and insular cortex [15]. 
Results in the expanded sample 
are similar to the previous find-
ings by Spina et al. [15] with 
increased statistical power. The 
prominent atrophy in mutation 
carriers compared to NCs in the 
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degeneration occurs prior to clinical decline in 
mutation carriers, perhaps years before expect-
ed clinically significant decline. However, it is of 
importance to note that the sample size of the 
AC group prohibited voxel-based analysis, thus 
further studies should be done to increase the 
power of this analysis. 
[18F]FDG PET metabolism
Prior bvFTD studies have demonstrated hypo-
metabolism in frontal and temporal lobes, ante-
rior cingulate cortex, anterior insula, and sub-
cortical regions [16-23]. MSTD mutation 
carriers showed near symmetrical hypometab-
Figure 4. Anatomical overlap of GM atrophy and glucose hypometabolism in MAPT intron 10 +3 mutation carriers 
relative to non-carriers. The overlap of regions showing significantly reduced GM density (red) and [18F]FDG uptake 
(blue) for MAPT intron 10 +3 carriers relative to non-carriers is presented. Significant overlap is observed in the 
medial temporal lobe and other temporal regions, while little overlap is seen in cortical and striatal regions. Images 
shown here are displayed at a voxel-wise threshold of p < 0.001 (uncorrected for multiple comparisons) for GM 
density and p < 0.01 (uncorrected for multiple comparisons) for glucose uptake, both with minimum cluster size (k) 
= 50 voxels. The GM density comparison was covaried for age, gender, and total intracranial volume, while the [18F]
FDG PET analysis was covaried for age and gender.
Figure 5. Relationship between medial temporal lobe (MTL) atrophy and hypometabolism in carriers and non-carri-
ers of the MAPT intron 10 +3 mutation. A significant association between GM density and glucose metabolism in the 
left and right MTL was observed across and within groups. Individual data points represent raw GM density and [18F]
FDG SUVR values. The reported R-squared value corresponds to the correlation across all participants, covaried for 
age, gender, and total intracranial volume. Linear fits are shown for individual groups, including non-carriers (dotted 
line), asymptomatic carriers (dashed line), and symptomatic carriers (solid line).
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olism in the MTL, parietal cortex, and frontal 
cortex relative to NCs. Consistent with the diag-
nosis for probable bvFTD [14], anterior tempo-
ral hypometabolism was observed, aff- 
ecting the right hemisphere more than the left. 
Several subcortical structures, many of which 
belong to the limbic system known to regulate 
emotion and memory, showed glucose hypo-
metabolism in the MAPT intron 10 +3 mutation 
carriers when compared to NCs, consistent 
with the clinical presentation of these partici-
pants. These regions include the cingulate 
gyrus, uncus, parahippocampal gyri, entorhinal 
cortex, and amygdala. The most notable reduc-
tion in glucose uptake was seen in the MTL, 
which is similar to other studies in FTDP-17T 
[24, 25]. Interestingly, glucose uptake in the AC 
group was between that of the NC and SC 
groups, suggesting a reduction in glucose 
metabolism prior to clinical decline. Utility of 
this FDG PET predictor biomarker will require 
future longitudinal follow-up studies. No signifi-
cant difference in glucose metabolism was 
observed between AC and SC, which may be a 
function of the small size of the AC group or 
may suggest the majority of the metabolic 
decline occurs prior to significant clinical symp-
tomatology. Larger samples and longitudinal 
follow-up should be completed to help resolve 
this issue.
Comparison of cortical atrophy and glucose 
metabolism
Cortical atrophy and hypometabolism in the 
MTL were strongly associated in the present 
study. The distribution of metabolic changes 
also overlaps previously described patterns of 
neurodegeneration in MSTD patients and are 
consistent with the clinical characteristics of 
their cognitive dysfunction [15]. The striking 
similarity between the MRI and [18F]FDG PET 
results and the high correlation of mean GM 
density and [18F]FDG uptake in this region also 
raises a question as to whether the observed 
hypometabolism is due to a reduction in local 
GM tissue in the MTL. However, given the 
marked effect of the MSTD mutation, it seems 
likely that the functional hypometabolism and 
structural neurodegenerative changes are 
occurring concurrently in these patients as two 
aspects of the underlying disease process. 
Both MTL glucose uptake and cortical atrophy 
in the AC group were intermediate between the 
NC and SC groups. The differences in cortical 
atrophy were significant between all groups, 
whereas the AC and SC participants were not 
significantly different in glucose uptake. In 
other words, the hypometabolism in ACs before 
onset of clinical symptomatology is similar to 
SC, while the change in MTL atrophy is interme-
diate. These results suggest the possibility that 
hypometabolism may occur before atrophic 
changes are detectable, which would support 
the hypothesis that the change in metabolism 
is not of direct consequence of atrophy, as simi-
lar findings have been observed in a previous 
study of Alzheimer’s disease [37]. The lack of 
observable atrophy in hypometabolic regions in 
the anterior cingulate cortex and caudate 
nucleus also support the hypothesis that dys-
functional glucose metabolism may precede 
atrophy in disease-associated regions. 
However, these differences between cortical 
atrophy and glucose metabolism, or lack there-
of, could also be due to different variability in 
the [18F]FDG PET and structural MRI measures, 
which complicates interpretation. 
As previously indicated, the present study con-
tains limitations. First, the AC group was small, 
which permitted quantitative ROI analysis but 
not voxel-based mapping of differences 
between the three groups. Further studies with 
a larger samples would provide the power 
needed to better detect the structural and met-
abolic differences in ACs and would offer a bet-
ter assessment of the impact of mutation sta-
tus and clinical symptoms on the relative rates 
of cortical atrophy and cognitive dysfunction. 
Additionally, it is possible that the hypometabo-
lism observed by the mutation-positive group 
was an effect of the cortical atrophy, as quanti-
tative analysis of the MTL also showed the two 
variables (metabolism, atrophy) were highly 
correlated. While mutation status appeared to 
be causal for both the lower GM density and 
glucose uptake, once again, the small sample 
size of the AC group prevented us from having 
the power to fully determine the topography of 
differences across groups. Prospective longitu-
dinal studies will be important in order to inves-
tigate the temporal relationships between met-
abolic and structural neuroimaging changes. 
Other functional imaging modalities could also 
prove informative with regard to early changes 
in brain networks, activation dynamics, and 
regional cerebral blood flow. Future studies 
with recently developed tau-specific PET trac-
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ers are also likely to elucidate the pattern of 
early changes and may provide better predic-
tion of neurodegeneration and cognitive decline 
[38, 39]. Overall, these results suggest that 
neuroimaging, in addition to genetic testing, 
may provide useful insights into the sequence 
of disease processes and characterization of 
the effects of MAPT mutation, especially in the 
prodromal stage of MSTD. 
In summary, cortical atrophy and hypometabo-
lism were observed in MSTD patients, especial-
ly in the MTL. These changes in brain structure 
and function are consistent with the observed 
cognitive dysfunction in these patients. Fur- 
thermore, reduced glucose metabolism and 
atrophy in the MTL were observed in ACs, sug-
gesting these changes precede clinical onset. 
Future studies of expanded samples with longi-
tudinal follow-up are needed to replicate the 
observed results and further elucidate the role 
of structural and functional brain changes in 
patients with MSTD. 
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